TLDR
- Hims & Hers (HIMS) stock surged over 44% in premarket trading Monday after Bloomberg reported Novo Nordisk plans to sell weight-loss drugs on its platform
- The two companies could announce the partnership as early as Monday
- The deal marks a reversal after Novo sued Hims in February over a copycat version of its oral Wegovy pill
- Leerink analyst Michael Cherny called it “both a surprise and an unabashed positive for HIMS’ stock” but kept a Market Perform rating
- Morgan Stanley’s Craig Hettenbach said the deal could ease legal and regulatory risks that had been weighing on the heavily shorted stock
Hims & Hers Health (HIMS) stock jumped more than 44% in premarket trading on Monday after Bloomberg reported that Novo Nordisk is planning to sell its weight-loss drugs through the Hims platform.
Novo Nordisk $NVO and Hims & Hers $HIMS end their legal feud and will sell obesity drugs together, per Bloomberg.
Partnership expected to be announced as soon as Monday.
HIMS stock is up 41% After hours….wow pic.twitter.com/fxvCnTSuei— Robert Fekete (@rokajoska) March 7, 2026
The report said an official announcement could come as early as Monday. The news sent HIMS rocketing higher, while Novo’s Copenhagen-listed stock climbed around 1%.
Hims & Hers Health, Inc., HIMS
This is a sharp turnaround for a stock that had already fallen about 51% this year before Monday’s move.
The deal would allow Novo’s obesity treatments — including drugs tied to its Ozempic and Wegovy brands — to be offered directly on the Hims platform. That’s a big shift given the bad blood between the two companies in recent months.
Novo sued Hims in February after the telehealth company launched a copycat version of Novo’s oral Wegovy weight-loss pill. Novo argued the product infringed on patents tied to its blockbuster medications.
The lawsuit was just the latest clash between them. Novo had previously accused Hims of continuing to market compounded versions of its drugs even after the two had an earlier falling out.
Analyst Reaction
Leerink analyst Michael Cherny called the development “both a surprise and an unabashed positive for HIMS’ stock.” He said the deal may prevent what had looked like “a protracted legal process that could include a full trial.”
But Cherny stopped short of turning bullish. “Even with this positive news, we do not see this as a clearing event for HIMS to fully recapture its growth potential,” he wrote, keeping a Market Perform rating on the stock.
Morgan Stanley analyst Craig Hettenbach took a similar view. He said the partnership could ease one of the biggest overhangs on HIMS — the regulatory and legal risks tied to its weight-loss business.
Hettenbach added that “any reduction in those risks could lead to a strong reband in the heavily shorted stock.”
Background on Compounded Drugs
Telehealth companies like Hims were able to sell lower-cost compounded copies of Novo and Eli Lilly weight-loss drugs during a period when branded supplies were short.
Those shortages have since ended. Regulators expected compounding to stop, but some telehealth companies kept going by tweaking dosages or ingredients to try to differentiate their products from the branded versions.
That’s what put Hims in Novo’s crosshairs earlier this year.
The new agreement, if confirmed, would essentially flip that relationship — turning Hims from a competitor into a distribution partner for Novo’s drugs.
Novo’s Copenhagen-listed stock was up around 1% on the news as of early Monday morning.
Considering a new stock? You may want to see what’s on our watchlist first.
Our team at Knockout Stocks follows top-performing analysts and market-moving trends to spot potential winners early. We’ve identified five stocks gaining quiet attention that could be worth watching now. Create your free account to unlock the full report and get ongoing stock insights.Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
